Ma Jun-Feng, Gao Jian-Ping, Shao Zi-Wei
Department of Surgical Oncology, Gansu Provincial Hospital, Lanzhou 730030, Gansu Province, China.
World J Stem Cells. 2023 Jan 26;15(1):1-15. doi: 10.4252/wjsc.v15.i1.1.
The therapeutic effects of various stem cells in acute liver failure (ALF) have been demonstrated in preclinical studies. However, the specific type of stem cells with the highest therapeutic potential has not been determined.
To validate the efficacy of stem cells in ALF model and to identify the most promising stem cells.
A search was conducted on the PubMed, Web of Science, Embase, Scopus, and Cochrane databases from inception to May 3, 2022, and updated on November 16, 2022 to identify relevant studies. Two independent reviewers performed the literature search, identification, screening, quality assessment, and data extraction.
A total of 89 animal studies were included in the analysis. The results of traditional meta-analysis showed that stem cell therapy could significantly reduce the serum levels of alanine aminotransferase [weighted mean difference (WMD) = -181.05 (-191.71, -170.39)], aspartate aminotransferase [WMD = -309.04 (-328.45, -289.63)], tumor necrosis factor-alpha [WMD = -8.75 (-9.93, -7.56)], and interleukin-6 [WMD = -10.43 (-12.11, -8.76)] in animal models of ALF. Further subgroup analysis and network meta-analysis showed that although mesenchymal stem cells are the current research hotspot, the effect of liver stem cells (LSCs) on improving liver function is significantly better than that of the other five types of stem cells. In addition, the ranking results showed that the possibility of LSCs improving liver function ranked first. This fully proves the great therapeutic potential of LSCs, which needs to be paid more attention in the future.
LSCs may have a higher therapeutic potential. Further high-quality animal experiments are needed to explore the most effective stem cells for ALF.
多种干细胞在急性肝衰竭（ALF）中的治疗效果已在临床前研究中得到证实。然而，治疗潜力最高的特定干细胞类型尚未确定。
验证干细胞在ALF模型中的疗效，并确定最有前景的干细胞。
对PubMed、Web of Science、Embase、Scopus和Cochrane数据库进行检索，检索时间从建库至2022年5月3日，并于2022年11月16日更新，以识别相关研究。由两名独立的评审员进行文献检索、识别、筛选、质量评估和数据提取。
分析共纳入89项动物研究。传统Meta分析结果显示，干细胞治疗可显著降低ALF动物模型血清中谷丙转氨酶[加权均数差（WMD）=-181.05（-191.71，-170.39）]、谷草转氨酶[WMD=-309.04（-328.45，-289.63）]、肿瘤坏死因子-α[WMD=-8.75（-9.93，-7.56）]和白细胞介素-6[WMD=-10.43（-12.11，-8.76）]的水平。进一步的亚组分析和网状Meta分析显示，尽管间充质干细胞是当前的研究热点，但肝干细胞（LSCs）改善肝功能的效果明显优于其他五种类型的干细胞。此外，排序结果显示LSCs改善肝功能的可能性排名第一。这充分证明了LSCs具有巨大的治疗潜力，未来需要更多关注。
LSCs可能具有更高的治疗潜力。需要进一步开展高质量的动物实验，以探索治疗ALF最有效的干细胞。
